Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults

Hannah E Maier,Theresa Kowalski-Dobson,Ashley Eckard,Carmen Gherasim,David Manthei,Alyssa Meyers,Dawson Davis,Kevin Bakker,Kathleen Lindsey,Zijin Chu,Lauren Warsinske,Matthew Arnold,Anna Buswinka,Emily Stoneman,Riccardo Valdez,Aubree Gordon
DOI: https://doi.org/10.1093/ofid/ofae039
2024-01-23
Open Forum Infectious Diseases
Abstract:Abstract Background The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. Methods The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Results Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Conclusions Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?